- Our Work
- Get Involved
A Stand Alone Study for Participants of A5175 (A Phase IV, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatme
Globally, 40 million individuals are HIV-infected with 5 million new infections occurring each year; rates are increasing. Three million individuals died from HIV/AIDS in 2003.
The global burden of the HIV epidemic is staggering, but in the short term, it is largely unfelt in the developed world. Ninety-five percent of new infections occur in the developing world (1). Almost 1 million people have been infected with HIV in North America (prevalence 0.6%). However, there are 25-28.2 million infected in sub-Saharan Africa alone; (prevalence 8.0%); 350,000-590,000 infected people in the Caribbean; 1.3-1.9 million in Latin America; and 4.6-8.2 million in South and Southeast Asia. The combined total number of people infected in the geographic areas represented by the ACTUs/AIACTUs and in the proposed sites within the International Neurology Consortium are in excess of 30 million.